Sage Therapeutics to report topline data from mid-stage study of SAGE-217 in PPD in Q4 [Seeking Alpha]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Seeking Alpha
Sage Therapeutics to report topline data from mid-stage study of SAGE-217 in PPD in Q4Sage Therapeutics (NASDAQ:SAGE)reports that it expects to announce topline data from a Phase 2 clinical trial evaluating SAGE-217 in women with postpartum depression (PPD) in Q4.SAGE-217, a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system (NYSE:CNS), plays a key role in regulating CNS function.It also expects the $575M proceeds from its planned stock offering, along with cash on hand and expected sales from brexolone IV, to be sufficient to fund operations into 2020.Previously:Sage Therapeutics launches mid-stage study of SAGE-217 in PPD (Dec. 19, 2016)Click to subscribe to real-time analytics on CNSNow read:Cohen & Steers, Inc. 2017 Q4 - Results - Earnings Call Slides »
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.MarketBeat
- Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at Morgan Stanley from $20.00 to $22.00. They now have an "equal weight" rating on the stock.MarketBeat
- Sage Therapeutics to Present at Upcoming March Investor ConferencesBusiness Wire
- Huntington's Disease Treatment Market Size to Worth USD 1,217.10 Million by 2032 [Yahoo! Finance]Yahoo! Finance
SAGE
Earnings
- 2/14/24 - Beat
SAGE
Sec Filings
- 3/27/24 - Form SC
- 3/26/24 - Form 8-K
- 2/21/24 - Form SC
- SAGE's page on the SEC website